Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
Tuberculosis
•
Pulmonology
•
Pulmonary Infections
•
HIV & AIDS
•
Hospital Medicine
Do you rule out TB in patients with AIDS and lobar pneumonia?
What’s your threshold to get the three AFBs and place the patient in airborne isolation?
Answer from: at Community Practice
Depends: +Ve Risk Factors: Travel/contact Hx, recent Quantiferon Conversion, changing CXR, Night sweats Unexplained low-grade temps Then, yes. Otherwise, no.
Sign in or Register to read more
17976
Related Questions
Do you consider the use of tocilizumab in patients with COVID pneumonia who have had an improvement in supplemental O2 requirements but have significantly elevated inflammatory markers after day two of remdesivir and dexamethasone?
What is the interpretation of two IGRAs with negative mitogen wells, in the absence of immunosuppression?
What is the interpretation of an IGRA with positive TB wells and negative nil and negative mitogen wells?
Are there situations where you would consider treating E faecalis or E faecium that grows from a respiratory culture?
How do you manage resistant infections that persist after stopping antibiotic therapy in patients with non-CF bronchiectasis?
Do you always stop dexamethasone at discharge for patients admitted with COVID requiring respiratory support (as done in the RECOVERY trial), or are there situations in which you will prescribe it to complete a 10-day course?
What further evaluation do you pursue for patients who present with vague symptoms such as subjective fevers or intermittent night sweats, who have no pulmonary symptoms but have a positive IGRA?
How would you treat an asymptomatic patient with a positive Blastomyces antibody, evidence of prior granulomatous lung disease on imaging, and who may require immunosuppression in the future?
Do you routinely discontinue atypical coverage in community-acquired pneumonia when PCR testing (i.e., respiratory pathogen panel) is negative for atypical organisms?
What is your preferred agent for fungal prophylaxis in a patient post lung transplant with abnormal LFTs?